No. 1 is SCBGENOME(E) +49.91%
กองทุนเปิดกรุงศรีโกลบอลเฮลธ์แคร์อิควิตี้เฮดจ์เอฟเอ็กซ์-ผู้ลงทุนสถาบัน
Shows where this fund stands in its group. Not investment advice · Data as of 16 Nov 2026
KFHHCARE-I invests through the master fund JPMorgan Funds - Global Healthcare Fund 99.62%
This fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per JPMorgan fact sheet
Over the past year it was below its group median; over 5 years it returned +0.56% per year (Above the median)
| Return | MDD | |
|---|---|---|
| YTD | +10.70% | −10.72% |
| 1D | +0.83% | 0.00% |
| 1W | +1.16% | −0.38% |
| 2W | +3.21% | −3.41% |
| 1M | +7.33% | −3.41% |
| 3M | +8.75% | −8.45% |
| 6M | +17.79% | −8.45% |
| Return | SD | MDD | Return/SD | |
|---|---|---|---|---|
| 1Y | +12.77% | 15.82% | −10.72% | +0.81 |
| 3Y | +24.70%+7.63%/yr | 14.46% | −22.80% | +0.53 |
| 5Y | +2.85% |
No. 1 is SCBGENOME(E) +49.91%
Past performance is not a guarantee of future results
Tap a year to see its months · * part year
Largest drawdown in the selected period −23.11% Previous peak 30 Dec 2021 (NAV 14.7968) → Trough 15 May 2025 (NAV 11.3778) · Back to the previous peak on 4 Nov 2026, after 1 year 5 months
Currently −0.61% from the peak NAV of 15.0897 (5 Nov 2026)
Over 1 year, KFHHCARE-I returned 0.81 per unit of SD, ranking 27 of 40 funds · The highest is KFHEALTH-A (1.34)
กองทุนจะลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศที่มีเป้าหมายให้ผลตอบแทนในการถือครองหน่วยลงทุนในระยะยาว โดยจะลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว Its largest holdings are Eli Lilly 8.00% · AbbVie 7.30% · Johnson & Johnson 6.30% (fact sheet 30 Oct 2026)
Risk level 7 of 8 (High risk). Since 15 Nov 2021, its NAV has fallen as much as −23.11% from its peak.
Actual total expense ratio (TER) 1.54% a year, against a ceiling of 4.65%. Management fee 1.34%. Front-end fee 0.00%. Back-end fee 0.00%. (Fact sheet 30 Sep 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase not set, subsequent purchases not set. Buy orders accepted until 15:30, sell orders until 14:30, and redemption proceeds are paid T+4
Almost fully hedged. As of 30 Oct 2026, 98.65% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · KFHHCARE-I: no dividends, TER 1.54% · KFHHCARE-A: no dividends, TER 1.54% · KFHHCARE-D: pays dividends, TER 1.54%
Warning Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements
Diabetes and weight-loss drugs
Hospitals, medicines and medical equipment
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
Hospitals, medicines and medical equipment
An American company selling scientific instruments, reagents and services for laboratories
Based on the master fund's share of this fund's value (99.62% as of 30 Sep 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from JPMorgan · Illustrations are for explanation only, not individual stock recommendations
| THB 500 |
| KFHHCARE-D | Pays | No | 1.54% | 1.50% | THB 500 |
| 15.80% |
| −23.11% |
| +0.04 |
| MAX | +2.23%+0.44%/yr | 15.79% | −23.11% | +0.03 |
| Return | MDD | SD | Return/SD | |
|---|---|---|---|---|
| 1Y | +12.77% | −10.72% | 15.82% | +0.81 |
| 3Y | +24.70%+7.63%/yr | −22.80% | 14.46% | +0.53 |
| 5Y | +2.85%+0.56%/yr | −23.11% | 15.80% | +0.04 |
| MAX | +2.23%+0.44%/yr | −23.11% | 15.79% | +0.03 |
No. 1 is TBIOTECH +23.13% per year
No. 1 is TBIOTECH +7.82% per year
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Only No tax benefit share classes are counted, and only funds with a full track record for the period are included · Calculated from NAV as of 16 Nov 2026